In a patient taking olanzapine who has weight gain and hyperphagia but no type 2 diabetes mellitus, heart failure, or chronic kidney disease, can dapagliflozin be used?

Dapagliflozin for Olanzapine-Induced Weight Gain and Hyperphagia

Direct Answer

Dapagliflozin is not indicated for olanzapine-induced weight gain and hyperphagia in patients without diabetes, heart failure, or chronic kidney disease, and should not be used for this purpose. The FDA-approved indications for dapagliflozin are limited to chronic kidney disease, heart failure, and type 2 diabetes—none of which include weight management or appetite suppression 1.

---

FDA-Approved Indications for Dapagliflozin

Dapagliflozin is approved only for:

• Chronic kidney disease (to reduce risk of kidney disease progression, end-stage kidney disease, cardiovascular death, and heart failure hospitalization) 1
• Heart failure (to reduce cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure regardless of ejection fraction) 1
• Type 2 diabetes (along with diet and exercise to improve glycemic control in adults and children ≥10 years) 1

Dapagliflozin is explicitly not approved for weight management or treatment of medication-induced weight gain 1.

---

Why Dapagliflozin Should Not Be Used for This Indication

Lack of Evidence for Weight Management Without Comorbidities

• The cardiovascular and renal benefits of dapagliflozin demonstrated in DAPA-CKD and DAPA-HF trials were in patients with established chronic kidney disease (eGFR 25-75 mL/min/1.73 m² with albuminuria) or heart failure—not in metabolically healthy individuals with isolated weight gain 2, 3.
• No randomized controlled trials have evaluated dapagliflozin specifically for antipsychotic-induced weight gain or hyperphagia 2, 3.

Safety Concerns in Patients Without Target Conditions

• Euglycemic diabetic ketoacidosis can occur even with normal blood glucose levels, particularly during illness, reduced food intake, or surgical procedures 1.
• Volume depletion leading to dizziness, orthostatic hypotension, and acute kidney injury is a recognized risk, especially in patients on concurrent diuretics or low-salt diets 1.
• Genital mycotic infections occur in approximately 6% of patients versus 1% with placebo 1.
• These risks are justified when treating life-threatening conditions like heart failure or progressive kidney disease, but not for isolated weight management 1.

---

Guideline-Recommended Approach to Olanzapine-Induced Weight Gain

First-Line Strategy: Medication Review and Alternatives

• The American Diabetes Association recommends that healthcare professionals minimize or provide alternatives for medications that promote weight gain whenever possible 4.
• Antipsychotics associated with weight gain include clozapine, olanzapine, and risperidone 4.
• Consider switching to a weight-neutral or weight-reducing antipsychotic (e.g., aripiprazole, ziprasidone, lurasidone) in consultation with the prescribing psychiatrist, if clinically appropriate 4.

Approved Weight Management Pharmacotherapy

• For patients with BMI ≥30 kg/m² or ≥27 kg/m² with obesity-related comorbidities, the American Diabetes Association recommends GLP-1 receptor agonists (semaglutide or tirzepatide) as preferred pharmacotherapy for weight management 4.
• These agents have demonstrated superior weight loss efficacy and added cardiometabolic benefits compared to other weight management medications 4.
• Liraglutide 3.0 mg and semaglutide 2.4 mg are FDA-approved specifically for chronic weight management and have robust evidence for cardiovascular risk reduction 4.

Structured Lifestyle Interventions

• Intensive behavioral therapy with reduced-calorie eating patterns and increased physical activity should be implemented alongside any pharmacotherapy 4.
• Weight management pharmacotherapy should be continued long-term to maintain benefits; sudden discontinuation often results in weight regain and worsening cardiometabolic risk factors 4.

---

Common Pitfalls to Avoid

• Do not prescribe dapagliflozin off-label for weight management in patients without diabetes, heart failure, or chronic kidney disease—this exposes patients to unnecessary risks without evidence of benefit 1.
• Do not assume that SGLT2 inhibitors are appropriate weight-loss agents simply because they cause modest weight reduction in diabetic patients—the mechanism (glucosuria) requires hyperglycemia to be effective 1.
• Do not overlook FDA-approved weight management medications (GLP-1 receptor agonists) that have demonstrated efficacy and safety specifically for obesity treatment 4.

---

Clinical Decision Algorithm

For a patient on olanzapine with weight gain and hyperphagia but no diabetes, heart failure, or CKD:

1. Assess psychiatric stability and consult with the prescribing psychiatrist about switching to a weight-neutral antipsychotic 4.
2. If antipsychotic cannot be changed:
   • Calculate BMI and assess for obesity-related comorbidities 4.
   • If BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities: Initiate a GLP-1 receptor agonist (semaglutide 2.4 mg weekly or tirzepatide) for weight management 4.
   • Implement structured lifestyle interventions with reduced-calorie diet and increased physical activity 4.
3. Do not use dapagliflozin for this indication—it is not approved, not evidence-based, and exposes the patient to unnecessary risks 1.